Abstract
Treatment with histone deacetylase inhibitors (HDACI) results in potent cytotoxicity of a variety of cancer cell types, and these drugs are used clinically to treat hematological tumors. They are known to repress the transcription of ERBB2 and many other oncogenes, but little is known about this mechanism. Using global run-on sequencing (GRO-seq) to measure nascent transcription, we find that HDACI cause transcriptional repression by blocking RNA polymerase II elongation. Our data show that HDACI preferentially repress the transcription of highly expressed genes as well as high copy number genes in HER2+ breast cancer genomes. In contrast, genes that are activated by HDACI are moderately expressed. We analyzed gene copy number in combination with microarray and GRO-seq analysis of expression level, in normal and breast cancer cells to show that high copy number genes are more likely to be repressed by HDACI than non-amplified genes. The inhibition of transcription of amplified oncogenes, which promote survival and proliferation of cancer cells, might explain the cancer-specific lethality of HDACI, and may represent a general therapeutic strategy for cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Federico M, Bagella L . Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol 2011; 2011: 475641.
Petrella A, Fontanella B, Carratu A, Bizzarro V, Rodriquez M, Parente L . Histone deacetylase inhibitors in the treatment of hematological malignancies. Mini Rev Med Chem 2011; 11: 519–527.
Khan O, La Thangue NB . HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90: 85–94.
Rikiishi H . Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011; 2011: 830260.
Kozikowski AP, Tapadar S, Luchini DN, Kim KH, Billadeau DD . Use of the nitrile oxide cycloaddition (NOC) reaction for molecular probe generation: a new class of enzyme selective histone deacetylase inhibitors (HDACIs) showing picomolar activity at HDAC6. J Med Chem 2008; 51: 4370–4373.
Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008; 409: 581–589.
Choudhary C, Kumar C, Gnad F, Nielsen ML, Rehman M, Walther TC et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009; 325: 834–840.
Berger SL . The complex language of chromatin regulation during transcription. Nature 2007; 447: 407–412.
Marchion D, Munster P . Development of histone deacetylase inhibitors for cancer treatment. Exp Rev Anticancer Ther 2007; 7: 583–598.
Reid G, Metivier R, Lin CY, Denger S, Ibberson D, Ivacevic T et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene 2005; 24: 4894–4907.
Xu WS, Parmigiani RB, Marks PA . Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541–5552.
Chou CW, Wu MS, Huang WC, Chen CC . HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PloS ONE 2011; 6: e18087.
LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A et al. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res 2011; 71: 3635–3648.
Scott GK, Marx C, Berger CE, Saunders LR, Verdin E, Schafer S et al. Destabilization of ERBB2 transcripts by targeting 3′ untranslated region messenger RNA associated HuR and histone deacetylase-6. Mol Cancer Res 2008; 6: 1250–1258.
Yokoyama S, Feige E, Poling LL, Levy C, Widlund HR, Khaled M et al. Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage. Pigment Cell Melanoma Res 2008; 21: 457–463.
Albertson DG . Gene amplification in cancer. Trends Genet 2006; 22: 447–455.
Huang X, Gao L, Wang S, Lee CK, Ordentlich P, Liu B . HDAC inhibitor SNDX-275 induces apoptosis in erbB2-overexpressing breast cancer cells via down-regulation of erbB3 expression. Cancer Res 2009; 69: 8403–8411.
Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B . Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat Methods 2008; 5: 621–628.
Huang da W, Sherman BT, Lempicki RA . Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44–57.
Huang da W, Sherman BT, Lempicki RA . Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1–13.
Gilmour DS, Fan R . Detecting transcriptionally engaged RNA polymerase in eukaryotic cells with permanganate genomic footprinting. Methods 2009; 48: 368–374.
Core LJ, Waterfall JJ, Lis JT . Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 2008; 322: 1845–1848.
Core LJ, Lis JT . Transcription regulation through promoter-proximal pausing of RNA polymerase II. Science 2008; 319: 1791–1792.
Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB et al. c-Myc regulates transcriptional pause release. Cell 2010; 141: 432–445.
Yik JH, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q . Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA polymerase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol Cell 2003; 12: 971–982.
Michels AA, Fraldi A, Li Q, Adamson TE, Bonnet F, Nguyen VT et al. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. Embo J 2004; 23: 2608–2619.
Liu Z, Li A, Schulz V, Chen M, Tuck D . MixHMM: inferring copy number variation and allelic imbalance using SNP arrays and tumor samples mixed with stromal cells. PloS ONE 2010; 5: e10909.
Govind CK, Qiu H, Ginsburg DS, Ruan C, Hofmeyer K, Hu C et al. Phosphorylated Pol II CTD recruits multiple HDACs, including Rpd3C(S), for methylation-dependent deacetylation of ORF nucleosomes. Mol Cell 2010; 39: 234–246.
Li B, Gogol M, Carey M, Lee D, Seidel C, Workman JL . Combined action of PHD and chromo domains directs the Rpd3S HDAC to transcribed chromatin. Science 2007; 316: 1050–1054.
Wang Z, Zang C, Cui K, Schones DE, Barski A, Peng W et al. Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes. Cell 2009; 138: 1019–1031.
Sawarkar R, Sievers C, Paro R . Hsp90 globally targets paused RNA polymerase to regulate gene expression in response to environmental stimuli. Cell 2012; 149: 807–818.
Sollars V, Lu X, Xiao L, Wang X, Garfinkel MD, Ruden DM . Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution. Nat Genet 2003; 33: 70–74.
Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM et al. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000; 275: 28345–28348.
Cheng B, Price DH . Properties of RNA polymerase II elongation complexes before and after the P-TEFb-mediated transition into productive elongation. J Biol Chem 2007; 282: 21901–21912.
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904–917.
Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011; 478: 524–528.
Kim YJ, Cecchini KR, Kim TH . Conserved, developmentally regulated mechanism couples chromosomal looping and heterochromatin barrier activity at the homeobox gene A locus. Proc Natl Acad Sci USA 2011; 108: 7391–7396.
Langmead B, Trapnell C, Pop M, Salzberg SL . Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol 2009; 10: R25.
Acknowledgements
We thank the members of the laboratory for their comments on the manuscript. Yale Center for Genomic Analysis provided services for microarray labeling, hybridization and scanning. Bing Ren (Ludwig Institute for Cancer Research, La Jolla, CA, USA) provided critical help with sequencing the GRO-seq libraries. CBG is a PhRMA Foundation predoctoral fellow. Grants to THK from the Rita Allen Foundation, Sidney Kimmel Foundation for Cancer Research, Yale Comprehensive Cancer Center (CA-16359), Alexander and Margaret Stewart Trust supported this work. A portion of this work was also made possible by a grant from the National Cancer Institute (R01CA140485 to THK).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Accession numbers
All the sequencing and array data have been submitted to the ArrayExpress archive. The accession numbers are E-MTAB-666, E-MTAB-667, E-MTAB-668 and E-MTAB-675.
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Kim, Y., Greer, C., Cecchini, K. et al. HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade. Oncogene 32, 2828–2835 (2013). https://doi.org/10.1038/onc.2013.32
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.32
Keywords
This article is cited by
-
Epigenetic targeting of the ACE2 and NRP1 viral receptors limits SARS-CoV-2 infectivity
Clinical Epigenetics (2021)
-
HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells
Oncogene (2019)
-
A variant NuRD complex containing PWWP2A/B excludes MBD2/3 to regulate transcription at active genes
Nature Communications (2018)
-
HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer
Oncogene (2017)
-
miR-155 downregulates ErbB2 and suppresses ErbB2-induced malignant transformation of breast epithelial cells
Oncogene (2016)